Biotechnology group Bicycle Therapeutics has appointed Lee Kalowski as chief financial officer at a time when the company explores a new class of therapeutics based on its proprietary bicyclic peptide product platform.
Prior to joining Bicycle, Kalowski served as the chief financial officer of Tokia Pharmaceuticals, where he helped lead the company’s $105m initial public offering in 2014.
He said: “Bicycle has pioneered a revolutionary platform that has generated a new class of drugs designed to target diseases more effectively.
“I am trilled to be joining the company as the pipeline continues to expand and as the company transitions into a clinical-stage biotech.”
Kalowski has also served Credit Suisse as its vice president, global biotechnology equity research and he has also worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson.
Kevin Lee, chief executive officer of Bicycle Therapeutics, said: “We are delighted to welcome Lee to the Bicycle team at this exciting time for our company.
“He brings a wealh of experience working with biotech companies at all stages of their evolution, both as a wall street research analyst and as a public company CFO, and his insights will prove invaluable as we continue to grow our business, expand our pipeline and move our lead candidate, BT1718, into clinical development.”